On April 15, 2026, researchers at NYU Langone Health published a cover story in Nature revealing how cancer cells apply a family of proteins called AP-1 to rewire their gene activity in response to chemotherapy, creating a form of cellular memory that leads to drug resistance without permanent DNA changes.
The study challenges the long-held view that drug resistance arises mainly from rare genetic mutations, instead showing that cancer cells can rapidly explore different gene expression patterns through AP-1’s ability to form diverse protein dimers, each regulating a distinct set of genes.
How AP-1 acts as an internal evolutionary algorithm in cancer cells
According to first author Gustavo S. França, PhD, the AP-1 protein complex functions like an evolutionary algorithm inside each malignant cell, generating multiple ways to regulate genes and selecting the combination best suited to survive environmental stress such as chemotherapy exposure.
Evidence of early adaptive states in melanoma under targeted therapy
A separate study from the Institute for Systems Biology, published in Nature Communications, found that melanoma cells driven by BRAF mutations enter a temporary drug-tolerant state within hours of treatment, not waiting for mutations to emerge but instead launching an early survival program driven by stress signals like NF-κB and chromatin remodeling.
